INCYTE CORP — Director's Dealing 2025

Jul 2, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INCYTE CORP (INCY)
CIK: 0000879169
Period of Report: 2025-06-30

Reporting Person: Issa Mohamed Khairie (EVP, Head of US Oncology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-30	Common Stock	A	27812	—	Acquired	76483	Direct

Footnotes

F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years from the vesting commencement date of January 6, 2025. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2: Including the June 30, 2025 grant, this includes an aggregate of 76,483 shares of common stock issuable pursuant to previously reported RSUs that have not vested.